Centessa Pharmaceuticals(US:CNTA) Businesswire·2026-03-31 12:11Core Viewpoint - Halper Sadeh LLC is investigating whether Centessa Pharmaceuticals plc is obtaining a fair price for its shareholders in the proposed sale to Eli Lilly and Company for $38.00 in cash per share plus a contingent value right worth up to $9.00 based on certain milestones [3]. Group 1: Investigation Details - The investigation focuses on whether Centessa and its board violated federal securities laws and/or breached fiduciary duties by failing to secure the best possible price for shareholders, conduct a fair sales process, and disclose all material information necessary for shareholders to evaluate the transaction [5]. - The proposed transaction may include terms that could limit superior competing offers, potentially disadvantaging ordinary shareholders [1]. Group 2: Shareholder Rights - Shareholders are encouraged to contact Halper Sadeh LLC to discuss their rights and options at no cost, with the firm operating on a contingent fee basis [2][4]. - Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief and benefits on behalf of shareholders [6].